Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
暂无分享,去创建一个
[1] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[2] Paul M. Ridker,et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.
[3] Steven P Jones,et al. HMG‐CoA reductase inhibition protects the diabetic myocardium from ischemia‐reperfusion injury , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] A. M. Lefer,et al. A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid , 2001, British journal of pharmacology.
[5] Joerg Kallen,et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.
[6] U. Laufs,et al. HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species , 2001, Hypertension.
[7] A. M. Lefer,et al. Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein E—Deficient Mice , 2001, Circulation.
[8] M. Merlos,et al. Alternative binding assay of GP IIb/IIIa antagonists with a nonradioactive labeling method of platelets. , 2001, Thrombosis research.
[9] P. Ridker,et al. Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.
[10] U. Laufs,et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. , 2001, Molecular pharmacology.
[11] P. Shah,et al. Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.
[12] M Shiomi,et al. Statins Alter Smooth Muscle Cell Accumulation and Collagen Content in Established Atheroma of Watanabe Heritable Hyperlipidemic Rabbits , 2001, Circulation.
[13] A. Szczeklik,et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. , 2001, International journal of cardiology.
[14] A. M. Lefer,et al. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. , 2001, Cardiovascular research.
[15] P. Libby,et al. An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.
[16] T. Yamashita,et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. , 2001, Atherosclerosis.
[17] F. Mach,et al. Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.
[18] D. Harrison,et al. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.
[19] T. Lüscher,et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. , 2000, Journal of the American College of Cardiology.
[20] I. Shiojima,et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.
[21] K. Koh. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. , 2000, Cardiovascular research.
[22] T. Awata,et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. , 2000, Life sciences.
[23] H. Katus,et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. , 2000, Circulation.
[24] F. Bernini,et al. Pleiotropic effects of statins in atherosclerosis and diabetes. , 2000, Diabetes care.
[25] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[26] P. Libby,et al. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[27] F. Bernini,et al. Non-lipid-related effects of statins , 2000, Annals of medicine.
[28] H. Drexler,et al. Endothelial Dysfunction in Hypercholesterolemia: Mechanisms, Pathophysiological Importance, and Therapeutic Interventions , 2000, Seminars in thrombosis and hemostasis.
[29] M. Moskowitz,et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. , 2000, The Journal of clinical investigation.
[30] A. Gotto,et al. The evolving role of statins in the management of atherosclerosis. , 2000, Journal of the American College of Cardiology.
[31] S. Harris,et al. Stimulation of bone formation in vitro and in rodents by statins. , 1999, Science.
[32] J. Harenberg,et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. , 1999, Thrombosis research.
[33] U. Laufs,et al. 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27 Kip1 * , 1999, The Journal of Biological Chemistry.
[34] M. Pfeffer,et al. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .
[35] A. M. Lefer,et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. , 1999, Circulation.
[36] L. Badimón,et al. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[37] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[38] J. Schelling,et al. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. , 1999, The Journal of clinical investigation.
[39] J. Kastelein,et al. The future of best practice. , 1999, Atherosclerosis.
[40] A. Döring,et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.
[41] M. Pfeffer,et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.
[42] J. Egido,et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.
[43] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[44] M. Essig,et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. , 1998, Circulation research.
[45] L. Case,et al. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[46] U. Laufs,et al. Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.
[47] A. Ortiz,et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. , 1998, Circulation research.
[48] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[49] P. Ridker,et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.
[50] M. Moskowitz,et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[51] M. Mann,et al. Cell cycle progression: new therapeutic target for vascular proliferative disease. , 1998, Circulation.
[52] J. Navarro-Antolín,et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.
[53] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[54] C. Furberg,et al. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. , 1998, Atherosclerosis.
[55] P. Macfarlane,et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.
[56] U. Laufs,et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.
[57] A. Hall,et al. Rho GTPases and the actin cytoskeleton. , 1998, Science.
[58] A. Takeshita,et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. , 1997, Circulation.
[59] U. Laufs,et al. Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase* , 1997, The Journal of Biological Chemistry.
[60] A. Namboodiri,et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. , 1997, The Journal of clinical investigation.
[61] D. Harrison,et al. Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.
[62] Shuh Narumiya,et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.
[63] L. Van Aelst,et al. Rho GTPases and signaling networks. , 1997, Genes & development.
[64] T. Matsumura,et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. , 1997, Atherosclerosis.
[65] C. Sirtori,et al. Platelet α2‐adrenergic receptors in hypercholesterolemia: Relationship between binding studies and epinephrine‐induced platelet aggregation , 1997 .
[66] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[67] D. Green,et al. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.
[68] T. Imaizumi,et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.
[69] C. Sirtori,et al. Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation. , 1997, Clinical pharmacology and therapeutics.
[70] T. Totsuka,et al. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. , 1996, International journal of immunopharmacology.
[71] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[72] D. Strachan,et al. C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.
[73] L. Hengst,et al. Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.
[74] V. Petrov,et al. Influence of cholesterol-lowering on plasma membrane lipids and function. , 1996, Methods and findings in experimental and clinical pharmacology.
[75] B. Kasiske,et al. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? , 1996, The Lancet.
[76] D. Waters,et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.
[77] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[78] M J Davies,et al. Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. , 1995, European heart journal.
[79] A. M. Lefer,et al. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[80] V. Fuster. Elucidation off the role of plaque instability and rupture in acute coronary events , 1995 .
[81] V. Fuster,et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. , 1995, Circulation.
[82] L. Yeatman,et al. Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.
[83] D. Carrié,et al. Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. , 1995, European heart journal.
[84] P. Libby. Molecular bases of the acute coronary syndromes. , 1995, Circulation.
[85] A. Simon,et al. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[86] D. A. Hughes,et al. Control of signal transduction and morphogenesis by Ras. , 1995, Seminars in cell biology.
[87] W. Wesemann,et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. , 1995, Atherosclerosis.
[88] A. Yeung,et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.
[89] W. Weintraub,et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.
[90] J. Albers,et al. Types of Change in Coronary Stenosis Severity and Their Relative Importance in Overall Progression and Regression of Coronary Disease , 1994, Annals of the New York Academy of Sciences.
[91] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[92] J. Robotham,et al. The acute-phase response. , 1995, New horizons.
[93] D. Harrison,et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. , 1995, The Journal of clinical investigation.
[94] V. Fuster. Elucidation of the role of plaque instability and rupture in acute coronary events. , 1995, The American journal of cardiology.
[95] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[96] G. Davı̀,et al. Inhibition of throm☐ane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia , 1994 .
[97] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[98] V. Fuster,et al. Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.
[99] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[100] V. Fuster,et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. , 1994, Journal of the American College of Cardiology.
[101] A. Hall,et al. Small GTP-binding proteins and the regulation of the actin cytoskeleton. , 1994, Annual review of cell biology.
[102] J. Albers,et al. Lipid Lowering and Plaque Regression New Insights Into Prevention of Plaque Disruption and Clinical Events in Coronary Disease , 1993, Circulation.
[103] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[104] K Y Liang,et al. Serum cholesterol in young men and subsequent cardiovascular disease. , 1993, The New England journal of medicine.
[105] V. Fuster,et al. Clinical-pathological correlations of coronary disease progression and regression. , 1992, Circulation.
[106] S. Moncada,et al. S‐nitroso‐glutathione inhibits platelet activation in vitro and in vivo , 1992, British journal of pharmacology.
[107] A. Henney,et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[108] V. Fuster,et al. Pathogenesis of thrombosis in unstable angina. , 1991, The American journal of cardiology.
[109] P. Kubes,et al. Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[110] T Sandor,et al. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. , 1991, Circulation research.
[111] J. Badimón,et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. , 1990, Circulation.
[112] J Pekkanen,et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. , 1990, The New England journal of medicine.
[113] R B D'Agostino,et al. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. , 1990, The New England journal of medicine.
[114] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.
[115] K. Schrör. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. , 1990, Eicosanoids.
[116] G. V. R. Born,et al. INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES , 1989, The Lancet.
[117] J. Eidt,et al. Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications , 1989, Circulation.
[118] A. Hassid,et al. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.
[119] D. Jacobs,et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.
[120] L. Ignarro,et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[121] L Roy,et al. Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.
[122] Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. , 1982, JAMA.
[123] R. Lees,et al. Hypercholesterolemia and platelets. , 1978, Advances in experimental medicine and biology.
[124] W. Kannel,et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.
[125] W. Kannel,et al. Premature mortality from coronary heart disease. The Framingham study. , 1971, JAMA.